In the second case, a 40-year-old woman with a history of depression reported worsening mood symptoms, including fatigue, cognitive slowing, and suicidal thoughts, approximately two months after beginning semaglutide for diabetes management
The weight loss data confirm that continued treatment beyond 48 weeks produces additional weight reduction: The 28.7% at 68 weeks exceeds the 24.2% at 48 weeks from Phase 2, representing approximately 4.5 additional percentage points of weight loss over the additional 20 weeks of treatment
Heres a quick snapshot of what to know: Purpose : Primarily prescribed for chronic weight management
The FDA approved a different formulation of Semaglutide GLP-1, marketed as Wegovy, which is explicitly designed for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition, such as high blood pressure or type 2 diabetes
SAS Institute Inc., Cary, NC, USA)
10.1007/s10495-024-01979-w 170 WeiH.ZhangY.JiaY.ChenX.NiuT.ChatterjeeA.et al (2024)